Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 5:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 1,167 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pediatric Tumors Clear all
Withdrawn Phase 4 Interventional

Heart Safety Study of Ondansetron in Children Receiving Chemotherapy

NCT01896440
View directory record Official record
Conditions
Malignant Childhood Neoplasm
Interventions
Ondansetron
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
6 Months to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Oct 8, 2013 · Synced Oct 26, 2026, 5:38 PM EDT
Terminated Phase 1 Interventional Results available

A Phase 1 Trial of a Single ProHema® CB Product for Pediatric Patients With Hematologic Malignancies

NCT02354417
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Biological: ProHema-CB
Biological
Lead sponsor
Fate Therapeutics
Industry
Eligibility
1 Year to 18 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Duarte, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Oct 26, 2026, 5:38 PM EDT
Active, not recruiting Early Phase 1 Interventional

A Study of Venetoclax in Combination With Chemotherapy to Treat Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

NCT05386576
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Venetoclax
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 26, 2026, 5:38 PM EDT
Terminated Phase 1 Interventional Results available

Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma

NCT01747876
View directory record Official record
Conditions
Malignant Rhabdoid Tumors (MRT), Neuroblastoma
Interventions
LEE011
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Year to 21 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
6
States / cities
San Francisco, California • Atlanta, Georgia • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2019 · Synced Oct 26, 2026, 5:38 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors

NCT04774718
View directory record Official record
Conditions
ALK Fusion-positive Solid or CNS Tumors
Interventions
Alectinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Up to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
7
States / cities
Palo Alto, California • St. Petersburg, Florida • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 26, 2026, 5:38 PM EDT
Terminated Phase 1 Interventional Results available

Study of Lenalidomide With Vorinostat in Pediatric Patients With High Grade or Progressive CNS Tumors

NCT03050450
View directory record Official record
Conditions
Central Nervous System Tumors
Interventions
25 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®), 50 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®), 100 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®), 150 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®), 150 mg/m2 Lenalidomide (Revlimid®) and 230 mg/m2 Vorinostat (Zolinza®)
Drug
Lead sponsor
Johns Hopkins All Children's Hospital
Other
Eligibility
1 Year to 21 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Oct 26, 2026, 5:38 PM EDT
Completed Phase 2 Interventional Results available

Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas

NCT02343406
View directory record Official record
Conditions
Glioblastoma
Interventions
Depatuxizumab mafodotin, Temozolomide, Lomustine
Drug
Lead sponsor
AbbVie
Industry
Eligibility
Up to 99 Years
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
13
States / cities
Palo Alto, California • Aurora, Colorado • Denver, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated May 22, 2020 · Synced Oct 26, 2026, 5:38 PM EDT
Completed Phase 1 Interventional

Phase I and Pharmacokinetic Trial of Paclitaxel (Taxol) Given as a 3-Hour Infusion in Pediatric Patients With Refractory Malignancy

NCT00001387
View directory record Official record
Conditions
Neoplasms
Interventions
paclitaxel
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 26, 2026, 5:38 PM EDT
Recruiting No phase listed Observational

A Longitudinal Photo-Narrative Exploration of Hope During Phase 1/2 Clinical Trials For Pediatric Cancer

NCT07444216
View directory record Official record
Conditions
Cancer, Therapy-Related
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
12 Years and older
Enrollment
100 participants
Timeline
2026 – 2030
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 26, 2026, 5:38 PM EDT
Terminated Phase 2 Interventional Results available

Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma

NCT02518750
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Lymphoma, Non-Hodgkin's, Leukemia, T-Cell, Leukemia, B-Cell
Interventions
Dexamethasone, Panobinostat, Liposomal vincristine, Mitoxantrone, Peg-asparaginase, Bortezomib, Intrathecal Triples, High-dose methotrexate, 6-Mercaptopurine, High-dose cytarabine, Nelarabine, Cyclophosphamide, Etoposide, Clofarabine
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 26, 2026, 5:38 PM EDT
Withdrawn Phase 4 Interventional

Reducing Port Access Pain and Clinic Wait Time: An Evaluation of EMLA Cream Versus nüm™ Vapocoolant Spray

NCT06023368
View directory record Official record
Conditions
Pediatric Cancer
Interventions
Num Vapocoolant Spray, EMLA Cream
Drug
Lead sponsor
Marianne Hutti
Other
Eligibility
4 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Oct 26, 2026, 5:38 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Acute Concussion and Melatonin

NCT04731974
View directory record Official record
Conditions
Concussion, Mild, Concussion, Brain, Pediatric ALL
Interventions
Melatonin 3 MG, Placebo
Drug · Other
Lead sponsor
Children's National Research Institute
Other
Eligibility
12 Years to 18 Years
Enrollment
254 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Oct 26, 2026, 5:38 PM EDT
Recruiting Phase 1 Interventional

Niclosamide in Pediatric Patients With Relapsed and Refractory AML

NCT05188170
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML)
Interventions
Niclosamide
Drug
Lead sponsor
Stanford University
Other
Eligibility
2 Years to 30 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 26, 2026, 5:38 PM EDT
Completed Not applicable Interventional

Feasibility and Acceptability of Brief, Telehealth Cognitive Compensatory Training for Pediatric Cancer Patients

NCT05704790
View directory record Official record
Conditions
Pediatric Cancer
Interventions
Cognitive Compensatory Training
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
8 Years to 18 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Oct 26, 2026, 5:38 PM EDT
Terminated Phase 2 Interventional Results available

Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma

NCT01032070
View directory record Official record
Conditions
Recurrent or Refractory Pediatric Ependymoma
Interventions
erlotinib, etoposide
Drug
Lead sponsor
OSI Pharmaceuticals
Industry
Eligibility
1 Year to 21 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • Orange, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Oct 26, 2026, 5:38 PM EDT
Active, not recruiting No phase listed Observational

The iCat2, GAIN (Genomic Assessment Informs Novel Therapy) Consortium Study

NCT02520713
View directory record Official record
Conditions
Pediatric Solid Tumor
Interventions
Genetic testing and GAIN report
Genetic
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Up to 30 Years
Enrollment
825 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
12
States / cities
San Francisco, California • Aurora, Colorado • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 26, 2026, 5:38 PM EDT
Completed Phase 1 Interventional

Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors

NCT01682746
View directory record Official record
Conditions
Brain Tumor, Recurrent
Interventions
Photofrin (porfimer sodium) & photodynamic therapy.
Drug
Lead sponsor
Harry T Whelan, MD
Other
Eligibility
6 Months to 18 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Wauwatosa, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Oct 26, 2026, 5:38 PM EDT
Recruiting Phase 2 Interventional

Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)

NCT06458036
View directory record Official record
Conditions
Differentiated Thyroid Cancer, Pediatric Cancer, Cancer, Cancer, Thyroid
Interventions
Selpercatinib Monotherapy, 131I Therapy
Drug · Radiation
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Years to 25 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
5
States / cities
San Francisco, California • Philadelphia, Pennsylvania • Memphis, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 26, 2026, 5:38 PM EDT
Active, not recruiting Early Phase 1 Interventional

An English/Spanish Mobile Augmented Reality Pain Assessment App for Hispanic/Latino Pediatric Cancer Patients

NCT06635434
View directory record Official record
Conditions
Pain, Pediatric Cancer
Interventions
AR Pain assessment
Device
Lead sponsor
ALTality, Inc.
Industry
Eligibility
7 Years to 17 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2024 · Synced Oct 26, 2026, 5:38 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Pediatric Oncology Nutrition Intervention Trial

NCT06175273
View directory record Official record
Conditions
Pediatric Cancer, Nutrition Related Cancer, Nutrition Aspect of Cancer, Muscle Loss, Malnutrition, Child
Interventions
Oral Nutrition Supplement, Tube Feed, Cyproheptadine, Olanzapine, Standard of Care
Dietary Supplement · Drug · Other
Lead sponsor
Corey Hawes
Other
Eligibility
2 Years to 19 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 26, 2026, 5:38 PM EDT
Recruiting Phase 1 Interventional

Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling

NCT05857969
View directory record Official record
Conditions
Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Large Cell Lymphoma, Refractory Childhood Acute Lymphoblastic Leukemia, Refractory Childhood Hodgkin Lymphoma, Refractory Childhood Malignant Germ Cell Neoplasm, Recurrent Childhood Brain Tumor, Recurrent Childhood Brainstem Glioma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Childhood Ependymoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Gliosarcoma, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Childhood Malignant Solid Neoplasm, Recurrent Childhood Malignant Solid Neoplasm, Recurrent Childhood Malignant Neoplasm, Refractory Childhood Malignant Neoplasm
Interventions
Functional Precision Medicine
Device
Lead sponsor
Florida International University
Other
Eligibility
1 Day to 21 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 26, 2026, 5:38 PM EDT
Not listed Not applicable Interventional

Exercise Intervention in Adolescent and Young Adult Cancer Survivors

NCT04265638
View directory record Official record
Conditions
Long-term Effects Secondary to Cancer Therapy in Adults, Pediatric Cancer
Interventions
Exercise
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
15 Years to 39 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
3
States / cities
Carmel, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Oct 26, 2026, 5:38 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Stress and Coping in Caregivers of Younger Patients With Cancer

NCT02725385
View directory record Official record
Conditions
Anxiety, Depression
Interventions
Laboratory Biomarker Analysis, Physiologic Testing, Questionnaire Administration
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
2
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 26, 2026, 5:38 PM EDT
Terminated Early Phase 1 Interventional

FET-PET/MRI for Surgical Assessment of Pediatric Brain Tumors

NCT03451123
View directory record Official record
Conditions
Pediatric Brain Tumors
Interventions
FET PET/MRI
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
6 Years to 18 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Oct 26, 2026, 5:38 PM EDT